RTW Investments’s Arcturus Therapeutics ARCT Stock Holding History

RTW Investments’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-251,236	Closed	-$10.8M	–	105
2020 Q3	$10.8M	Buy	+251,236	New	+$12.5M	0.26%	62

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

RTW Investments's ARCT Position: Q4 2020 in Review

RTW Investments sold out of Arcturus Therapeutics (ARCT) in Q4 2020, closing a stake of 251,236 shares — an estimated $10.8M sold.

RTW Investments first reported a position in ARCT in Q3 2020 and held it in 1 quarter. The position peaked at $10.8M in Q3 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q4 2020.

RTW Investments reported no remaining Arcturus Therapeutics position as of Q4 2020 after selling out during the quarter.
RTW Investments sold 251,236 Arcturus Therapeutics shares in Q4 2020, an estimated $10.8M.
RTW Investments first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 1 quarter.
RTW Investments's Arcturus Therapeutics position peaked at $10.8M in Q3 2020.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2020.

Based on RTW Investments's 13F filing for Q4 2020, filed 16 Feb 2021.